StockWatch
·
Medical/Dental Instruments
Quarterly ResultMay 8, 2026, 04:52 PM

Femasys Q1 Net Income $846K vs. $(5.9M) Loss YoY

AI Summary

Femasys Inc. reported a net income of $846,100 for the first quarter of 2026, a substantial improvement compared to a net loss of $(5,896,839) in the same period last year. This income was significantly influenced by non-operating gains from changes in the fair value of conversion option and warrants liabilities. Sales for the quarter increased to $424,889. Despite the reported net income, the company's cash and cash equivalents decreased to $5,386,041, and management expressed substantial doubt about its ability to continue as a going concern due to an accumulated deficit and expected future operating losses.

Key Highlights

  • Reported Q1 2026 net income of $846,100, a significant improvement from a $(5,896,839) net loss in Q1 2025.
  • Sales increased to $424,889 in Q1 2026, up from $341,264 in the prior year period.
  • Cash and cash equivalents decreased to $5,386,041 as of March 31, 2026, from $9,266,353 at December 31, 2025.
  • Recognized a $3,683,000 gain from the change in fair value of warrants liabilities.
  • Recognized a $1,513,413 gain from the change in fair value of conversion option liability.
  • Research and development expenses decreased to $1,309,401 from $2,968,472 year-over-year.
  • Sales and marketing expenses increased to $1,315,755 from $908,567 year-over-year.
  • Company noted substantial doubt about its ability to continue as a going concern.